Conditions: Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 31
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and tolerability of IC83/LY2603618 for the treatment of cancer.

Detailed description:

Arms:
arm 1: LY2603618 40 milligrams per square meter (mg/m\^2) was administered over the duration of 4.5 hours (30-minute bolus followed by a 4-hour infusion). Dose modifications were not allowed. arm 2: Based on pharmacokinetic (PK) data from Cohort 1 (LY2603618 40 mg/m\^2 \[4.5-hour infusion\]), the LY2603618 40 mg/m\^2 dose in Cohort 2 (LY2603618 40 mg/m\^2 \[1-hour infusion\]) was repeated, but the dose was administered over the duration of 1 hour. Dose modifications were not allowed. arm 3: Beginning with Cohort 3 (LY2603618 70 mg/m\^2), dose modifications were allowed. LY2603618 70 mg/m\^2 was administered over the course of 1 hour. arm 4: Cohort 4: LY2603618 105 mg/m\^2 administered over the duration of 1 hour. arm 5: Cohort 5: LY2603618 150 mg/m\^2 administered over the duration of 1 hour. arm 6: Cohort 6: LY2603618 195 mg/m\^2 administered over the duration of 1 hour.

Interventions: intervention 1: IC83/LY2603618 intervention 2: IC83/LY2603618 intervention 3: IC83/LY2603618 intervention 4: IC83/LY2603618 intervention 5: IC83/LY2603618 intervention 6: pemetrexed intervention 7: pemetrexed
Intervention descriptions: intervention 1: 40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2. intervention 2: 70 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. intervention 3: 105 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. intervention 4: 150 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. intervention 5: 195 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. intervention 6: pemetrexed 500 mg/m\^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles intervention 7: pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles

Protocol document: